Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 4Prostatic Neoplasms 2Recurrence 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1

Interventions

Docetaxel 158Prednisone 131Leuprolide 95bicalutamide 86enzalutamide 83Radiotherapy 80Goserelin 80Abiraterone Acetate 76acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 54Magnetic Resonance Spectroscopy 46Zoledronic Acid 44gallium 68 PSMA-11 37Flutamide 34abiraterone 32Estramustine 32radium Ra 223 dichloride 30apalutamide 27Surveys and Questionnaires 26Gonadotropin-Releasing Hormone 26Androgen Antagonists 25cabazitaxel 24Radiosurgery 24Dutasteride 22sipuleucel-T 21Prednisolone 21Triptorelin Pamoate 20Paclitaxel 20luprolide acetate gel depot 19Radiation 19Exercise 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Prostatic Neoplasms × TroVax × Clear all
NCT02390063 2020-02-10

Vaccination in Prostate Cancer (VANCE)

University of Oxford

Phase 1 Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT00448409 2016-03-17

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

The Methodist Hospital Research Institute

Phase 2 Completed
27 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡